Regeneron Pharmaceuticals... (REGN)
NASDAQ: REGN
· Real-Time Price · USD
570.22
3.00 (0.53%)
At close: Sep 05, 2025, 3:00 PM
Regeneron Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 1.86B | 1.53B | 1.61B | 1.66B | 1.52B | 1.27B | 1.37B | 1.44B | 1.32B | 1.38B | n/a | 1.05B | 1.04B | 1.23B | 86.2M | 1.07B | 954.7M | 754.4M | 1.62B | 1.48B | 1.23B | 1.24B | 1.29B | 1.24B | 1.21B | 1.1B | 2.08B | 1.03B | 996.38M |
| Collaboration Revenue Revenue Growth | +21.52% | -4.71% | -3.20% | +8.93% | +20.30% | -7.53% | -4.75% | +9.24% | -4.46% | n/a | -100.00% | +0.67% | -15.33% | +1329.81% | -91.97% | +12.49% | +26.55% | -53.48% | +9.42% | +20.81% | -0.79% | -3.86% | +3.88% | +2.74% | +9.14% | -47.01% | +103.25% | +2.92% | n/a |
| Product and Service, Other Revenue | 183.9M | 81.9M | 179.4M | 114.2M | 104.5M | 116.9M | 212.5M | 138.3M | 69.3M | 116M | 127.7M | 84.2M | 59.2M | 94M | 3.98B | 99M | 46M | 50M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product and Service, Other Revenue Growth | +124.54% | -54.35% | +57.09% | +9.28% | -10.61% | -44.99% | +53.65% | +99.57% | -40.26% | -9.16% | +51.66% | +42.23% | -37.02% | -97.64% | +3915.35% | +115.22% | -8.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 1.63B | 1.42B | 2B | 1.95B | 1.92B | 1.76B | 1.85B | 1.79B | 1.77B | 1.67B | 1.7B | 1.8B | 1.75B | 1.64B | n/a | 2.28B | 4.14B | 1.72B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +15.22% | -29.32% | +2.90% | +1.45% | +8.93% | -4.89% | +3.68% | +0.79% | +6.24% | -1.84% | -5.67% | +2.68% | +7.07% | n/a | n/a | -44.90% | +139.97% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 634.2M | 633M | 783.7M | 714.4M | 758.8M | 689M | 704.4M | 640.5M | 652M | 601.1M | 657M | 529.1M | 476.3M | 450M | 559.6M | 445M | 414.7M | 405.6M | 303.5M | 326.9M | 348.3M | 367.3M | 586.8M | 304.4M | 294.6M | 291.1M | 491.3M | 369.23M | 364.88M | 330.77M | 409.91M | 306.77M | 306.91M | 296.85M | 325.94M | 270.05M | 292.04M | 289.68M | 294.95M | 209.99M | 174.59M | 158.99M |
| Selling, General, and Administrative Revenue Growth | +0.19% | -19.23% | +9.70% | -5.85% | +10.13% | -2.19% | +9.98% | -1.76% | +8.47% | -8.51% | +24.17% | +11.09% | +5.84% | -19.59% | +25.75% | +7.31% | +2.24% | +33.64% | -7.16% | -6.14% | -5.17% | -37.41% | +92.77% | +3.33% | +1.20% | -40.75% | +33.06% | +1.19% | +10.31% | -19.31% | +33.62% | -0.05% | +3.39% | -8.93% | +20.70% | -7.53% | +0.82% | -1.79% | +40.46% | +20.28% | +9.81% | n/a |
| Research and Development Revenue | 1.29B | 1.2B | 1.27B | 1.15B | 1.08B | 1.13B | 1.05B | 969.9M | 982.2M | 1B | 941.6M | 818.7M | 719.9M | 769.5M | 711.1M | 592.2M | 643.1M | 675.5M | 682.8M | 625.3M | 663.2M | 527.8M | 683.1M | 473.1M | 833.4M | 435.1M | 558.44M | 521.53M | 495.65M | 462.23M | 493.48M | 492.03M | 474.85M | 469.32M | 450.31M | 515.21M | 559.93M | 470.11M | 461.21M | 425.92M | 390.33M | 343.11M |
| Research and Development Revenue Growth | +7.17% | -5.61% | +10.62% | +6.53% | -4.85% | +7.97% | +8.32% | -1.25% | -1.95% | +6.38% | +15.01% | +13.72% | -6.45% | +8.21% | +20.08% | -7.91% | -4.80% | -1.07% | +9.20% | -5.71% | +25.65% | -22.73% | +44.39% | -43.23% | +91.54% | -22.09% | +7.08% | +5.22% | +7.23% | -6.33% | +0.29% | +3.62% | +1.18% | +4.22% | -12.60% | -7.99% | +19.11% | +1.93% | +8.28% | +9.12% | +13.76% | n/a |